期刊文献+

信号转导与转录激活因子3表达水平与垂体腺瘤各亚型的相关性 被引量:2

Correlation between Expression of Signal Transducer and Activator of Transcription 3 and Pituitary Adenoma Subtypes
下载PDF
导出
摘要 目的探讨信号转导与转录激活因子3(STAT3)表达水平和垂体腺瘤各亚型之间的相关性。方法应用实时定量PCR、Western blot以及免疫组织化学染色检测STAT3在垂体腺瘤各亚型的表达。结果 STAT3在垂体腺瘤各亚型均有表达,与其他类型肿瘤,包括催乳素、促卵泡激素/促黄体生成激素以及促肾上腺皮质激素腺瘤相比,STAT3在生长激素腺瘤表达最高,促卵泡激素/促黄体生成激素腺瘤表达最低。结论 STAT3在垂体腺瘤各亚型的差异表达表明STAT3调控的细胞特异性本质,这种特异性的调控机制值得进一步研究。 Objective To investigate the correlation between signal transducer and activator of transcription 3( STAT3) expression and pituitary adenoma subtypes. Method The STAT3 expression profiles in different pituitary adenomas from 74 patients were determined using quantificational real-time polymerase chain reaction,Western blot,and immunohistochemistry. Results Expression of STAT3 was observed in all pituitary adenoma subtypes. The STAT3 expression level was highest in growth hormone adenoma when compared with other tumors including prolactin,follicle-stimulating hormone / luteinizing hormone-secreting adenoma,and adrenocorticotrophic hormone-secreting adenoma. The follicle-stimulating hormone / luteinizing hormone adenomas exhibited the lowest STAT3 expression levels. Conclusion STAT3 is differentially expressed in pituitary adenoma subtypes,suggesting the cell-specific features of STAT3 regulation,although further investigations are still warranted to clarify the underlying mechanisms.
出处 《中国医学科学院学报》 CAS CSCD 北大核心 2015年第6期693-697,共5页 Acta Academiae Medicinae Sinicae
关键词 信号转导与转录激活因子3 促肾上腺皮质激素 生长激素 泌乳素 卵泡刺激素/黄体生成素 垂体腺瘤 signal transducer and activator of transcription 3 adrenocorticotropic hormone growth hormone prolactin follicle-stimulating hormone / luteinizing hormone pituitary adenoma
  • 相关文献

参考文献14

  • 1Darnell JE Jr, Kerr IM, Stark GR.Jak-STAT pathways and transcriptional activation in response to IFNs and other extra- cellular signaling proteins [J]. Science, 1994, 264(5164) : 1415-1421.
  • 2Aggarwal BB, Kunnumakkara AB, Harikumar KB, et al. Signal transducer and activator of transcription-3, inflamma- tion, and cancer: how intimate is the relationship? [J]. Ann NY Acad Sei, 2009, 1171:59-76.
  • 3Brornberg J. Stat proteins and oncogenesis [ J ]. J Clin In- vest, 2002, 109(9) :1139-1142.
  • 4Yue P, Turkson J. Targeting STAT3 in cancer: how success- ful are we? [J]. Expert Opin Inv Drug, 2009, 18 1): 45-56.
  • 5Wang X, Crowe PJ, Goldstein D, et al. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review) [J]. Int J Oncol, 2012, 41(4) :1181-1191.
  • 6Arzt E. gpl30 eytokine signaling in the pituitary gland: a paradigm for cytokine-neuro-endocrine pathways [ J ]. J Clin Invest, 2001, 108 (12) : 1729-1733.
  • 7Mynard V, Guignat L, Devin-Leelerc J, et al. Different mechanisms for leukemia inhibitory factor-dependent activa- tion of two proopiomelanoeortin promoter regions [ J ]. Endo- crinology, 2002, 143(10) :3916-3924.
  • 8Zhou CQ, Jiao YH, Wang RZ, et al. STAT3 upregulation in pituitary somatotroph adenomas induces growth hormone hyper- secretion [J]. J Clin Invest, 2015, 125(4) :1692-1702.
  • 9Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pi- tuitary adenomas: a systematic review [ J ]. Cancer, 2004, 101:613-619.
  • 10代从新,马四海,蔡锋,刘小海,姚勇,王任直.替莫唑胺治疗难治性垂体腺瘤的研究进展[J].中华神经外科杂志,2013,29(4):423-425. 被引量:1

二级参考文献34

  • 1Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas : a systematic review. Cancer,2004-, lO1:613-619.
  • 2Colao A, Grasso LF, Pivonello R, et al. Therapy of aggressive pit- uitary tumors. Expert Opin Pharmacother,2011,12 :1561-1570.
  • 3Zada G, Woodmansee WW, Ramkissoon S, et al. Atypical pit- uitary adenomas : incidence, clinical characteristics, and implications. J Neurosurg,2011,114 :336-344.
  • 4Syro LV, Ortiz LD, Scheithauer BW, et al. Treatment of pituitary neoplasms with temozolomide: a review. Cancer, 2011, 117: 454-462.
  • 5Villano JL, Seery TE, Bressler LR. Temozolomide in malignant gli- omas: current use and future targets. Caneer Chemother Pharmaeol, 2009,64 : 647 -655.
  • 6Bei R, MarzoeeheUa L, Turriziani M. The use of temozolomide for the treatment of malignant tumors: elinieal evidenee and molecular mechanisms of aetion. Recent Pat Antieancer Drug Discov,2010,5 : 172-187.
  • 7Syro LV, Scheithauer BW, Ortiz LD, et al. Effect of temozolomide in a patient with recurring oncocytie gonadotrophic pituitary adenoma. Hormones (Athens) ,2009,8:303-306.
  • 8Hagen C, Schroeder HD, Hansen S, et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. Eur J Endocrinol,2009,161 : 631-637.
  • 9Losa M, Mazza E, Terreni MR, et al. Salvage therapy with tem- ozolomide in patients with aggressive or metastatic pituitary adenomas:experience in six cases. Eur J Endocrinol,2010,163 : 843 -851.
  • 10Mohammed S, Kovaes K, Mason W, et al. Use of temozolomide in aggressive pituitary tumors: ease report. Neurosurgery, 2009, 64 :E773-E774 ;discussion E774.

同被引文献15

引证文献2

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部